Obesity is an excessive body fat which increase the risk of body or health. It is a medical condition caused due to an extreme level of food intake, genetic susceptibility, and lack of physical exercise. The drugs which are used in the treatment of obesity comprises of Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, and Liraglutide among others.
The global obesity management drugs market is assessed to account for US$ 764.7 Mn in terms of value in 2020 and is projected to reach US$ 1,078.9 Mn by the end of 2027.
Global Obesity Management Drugs Market: Drivers
High occurrence of obesity is expected to increase the growth of worldwide obesity the executive’s drugs market over the forecasting time frame. For example, as per MedAlertHelp.org, over 1.9 billion grown-ups were accounted for as overweight around the world.
Beside, R&D in fatness or obesity is expected to present at an e-ECE 2020, the 22nd European Congress of Endocrinology, the probiotic rinsing Bifidobacterium breve, in in combination with a calorie-controlled diet, may benefit children and adolescents grouping with fatness lose weight.
Orlistat apprehend on predominant footing in the worldwide corpulence the executives drugs market in 2019, representing 31.9% offer as far as worth, trailed by Liraglutide and Lorcaserin, individually.
Global Obesity Management Drugs Market: Restraints
Lack of appropriate medical care framework alongside ill-advised turn of events and execution of clinical practice rules and lack of talented workers in developing business sectors is relied upon to obstruct development of the worldwide stoutness the board drugs market.
Beside, significant expense related with improvement of heftiness medications and medical procedure is additionally expected to restrict the market development. Moreover, long incubation time required for innovative work exercises and the incorporation of clinical preliminaries needed to test the medications amount to critical use.
Global Obesity Management Drugs Market: Opportunities
Rise of Covid-19 is estimated to offer profitable development openings for major parts in the worldwide obesity management drugs market. For example, in September 2020, analysts from the University of North Carolina detailed that stoutness can expand the death rate in COVID-19 by almost half.
In addition, R&D of fatness is estimated to help in development of the worldwide obesity the management drugs market over the time frame. For example, in September 2020, an examination by Novo Nordisk A/S announced that GLP-1 medications, which help patients hold glucose levels in line, could be utilized in the treatment of Covid-19 in diabetic and hefty patients.
The global obesity management drugs market was esteemed at US$ 729.9 Mn in 2019 and is projection to reach a value of US$ 1,078.9 Mn by 2027 at a CAGR of 5.0% between 2020 and 2027.
Request PDF Brochure Report –
Market Trends/Key Takeaways
A few developed nations are deteriorating to diminish the occurrence of obesity. For example, in September 2020, as per a report by the National Audit Office, the U.K. government is required to fall flat in its main goal to divide youth stoutness in England by 2030.
High predominance of obesity in developing economies is required to drive development of the worldwide obesity management drugs market. For example, in September 2020, WellNewMe, a Nigerian wellbeing innovation organization, revealed that fatness had become an expanding wellbeing worry for some individuals in sub-Saharan Africa and featured that almost 33% of Nigerian ladies were either overweight or corpulent in 2018.
In the U.S., Federal Food Drugs and Cosmetics Act (FD&C Act) and Controlled Substances Act, or CSA oversee all the activities related to exclusive generics including development, manufacturing, testing, labelling, distribution, advertising & promotion, sales, import export of generic products
The manufacturer of branded generic products are essential to obtain abbreviated new drug application (ANDA) approval under section 505(b) (2) of Federal Food Drug and Cosmetics Act.
Necessities for acquiring ANDA are given in 21CFR314.54, which clarifies Procedure for accommodation of an application requiring examinations for endorsement of another sign for, or other change from, a recorded medication (trailblazer item recorded in Orange book)
Global Obesity Management Drugs Market: Competitive Landscape
Major players working in the global obesity management drugs market contain, F Hoffmann La Roche Ltd., GlaxoSmithKline plc. Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc., VIVUS, Inc., Novo Nordisk A/S, and Eisai Co., Ltd.
Global Obesity Management Drugs Market: Key Developments
Significant parts in the world obesity managemenrt drugs market are absorbed around embracing cooperation and association methodologies to extend their item portfolio. For example, in October 2018, Eisai Co., Ltd. entered a concurrence with Eurofarma Laboratories S.A. to give selective turn of events and advertising rights for its enemy of weight specialist, lorcaserin hydrochloride, in 17 nations in Latin America and the Caribbean, barring Brazil.
Buy This Complete A Business Report With Flat US $2000 Off @
Reasons to Purchase this Report
- Current and future of global Anti-Obesity Drugs market outlook in the developed and emerging markets
- The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
- Regions/countries that are expected to witness the fastest growth rates during the forecast period
- The latest developments, market shares, and strategies that are employed by the major market players
Major Point Answered in Anti-Obesity Drugs Market Research Study are:
What will be the progress rate of the Anti-Obesity Drugs Market for the conjecture period, 2020-2027?
What are the prominent factors driving the Anti-Obesity Drugs Market across different regions?
Who are the major vendors dominating the Anti-Obesity Drugs industry and what are their winning strategies?
What will be the market scope for the estimated period?
What are the major trends shaping the expansion of the industry in the coming years?
What are the challenges faced by the Anti-Obesity Drugs Market?
Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027